These are the stocks posting the largest moves before the bell.Market Insiderread more
Morgan Stanley analysts said the reduction was driven by concerns around Chinese demand for Tesla products.Autosread more
Boeing shares rose Tuesday after a Wall Street Journal report said aviation officials believe a bird strike may have caused the crash of a 737 Max in Ethiopia in March.Aerospace & Defenseread more
For every 5% drop in Greater China sales, Apple's earnings per share should fall about 15 cents, Credit Suisse tells clients.Investingread more
Alphabet Inc's Google said Tuesday that keeping phones up to date and secure was in "everyone's best interests," shortly after the U.S. temporarily eased some trade...Technologyread more
As tariff worries hit Apple, the stock has fallen into a bear market. But Joule Financial's Quint Tatro believes the pullback represents a buying opportunity, while...Trading Nationread more
Technology stocks are a casualty of the trade war, but analysts say there's a chance longer term some companies might emerge stronger, depending on what kind of deal is...Market Insiderread more
Home Depot on Tuesday reported fiscal first-quarter earnings that beat analysts expectations, despite a damp start to the spring in much of the U.S.Retailread more
Susquehanna has a neutral rating on the stock and a price target of $42 per share.Investingread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Once the hallmark of a struggling economy, layaway options are now aimed at encouraging young shoppers to buy more stuff.Personal Financeread more
CANTON, Mass., Aug. 7, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, August 13, 2015 at 8:00 a.m. ET. The Company will discuss its financial results for the second quarter of 2015 and provide a corporate update. Topics in the corporate update will include: commercial organization progress, the recently announced FDA Advisory Committee meeting for Xtampza™ ER and patent litigation with Purdue Pharma L.P.
Conference Call Information:
To access the conference call, please dial (866)864-3220 (U.S.) or (704)908-0478 (International). An audio webcast will be accessible from the Investor Relations section of the Company's website: http://www.collegiumpharma.com/. An archived webcast will be available on the Company's website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. The new drug application, or NDA, submission for Xtampza ER, the Company's lead product candidate, was accepted for review by the FDA on February 10, 2015. The FDA set a Prescription Drug User Fee Act, or PDUFA, goal date of October 12, 2015 for completion of its review of the Xtampza ER NDA.
CONTACT: Douglas Carlson Vice President, Corporate Development email@example.com